Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2 study of the monocyte-targeted histone deacetylase inhibitor tefinostat (CHR-2845) in chronic myelomonocytic leukaemia (CMML)

Next Previous
Trial Profile

A phase 2 study of the monocyte-targeted histone deacetylase inhibitor tefinostat (CHR-2845) in chronic myelomonocytic leukaemia (CMML)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tefinostat (Primary)
  • Indications Chronic myelomonocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MONOCLE

Most Recent Events

  • 04 Dec 2018 Results (n=21) assessing safety and efficacy of Tefinostat in Chronic Myelomonocytic Leukemia (CMML) patients, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
  • 23 Oct 2018 Planned number of patients has been changed from 40 to 20 as there were an insufficient number of objective clinical responses seen in part 1 of the study to reach the threshold required to trigger the opening of part 2. Therefore the trial never opened to the second stage and did not fulfil the overall study recruitment target of 40 patients
  • 23 Oct 2018 Planned number of patients changed from 40 to 20.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top